Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569909 | 0.80 | LPO (0.43) | LPOMCL1C1SHTTCHRM4 | |
| SCHEMBL5610390 | 0.78 | LPO (0.41) | LPOMCL1C1SHTTCHRM4 | |
| SCHEMBL5610393 | 0.78 | LPO (0.41) | LPOMCL1C1SHTTCHRM4 | |
| SCHEMBL9033147 | 0.78 | LPO (0.41) | LPOMCL1C1SHTTCHRM4 | |
| SCHEMBL20368151 | 0.77 | HTT (0.41) | LPOMCL1C1SHTTCHRM4 | |
| Hydrochloric Acid SCHEMBL28316626 | 0.77 | LPO (0.40) | LPOMCL1C1SHTTCHRM4 | |
| SCHEMBL24051973 | 0.75 | MCL1 (0.46) | LPOMCL1C1SHTTCHRM4 | |
| SCHEMBL20364513 | 0.75 | LPO (0.39) | LPOMCL1C1SHTTCHRM4 | |
| SCHEMBL22951445 | 0.75 | MCL1 (0.40) | LPOMCL1C1SHTTCHRM4 | |
| SCHEMBL24051974 | 0.75 | MCL1 (0.43) | LPOMCL1C1SHTTFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106558534-B | Structure and method for interconnection | 台湾积体电路制造股份有限公司 | 2020-07-31 | — | — | CN | claimed |
| CN-106653681-B | Autoregistration interconnection structure and method | 台湾积体电路制造股份有限公司 | 2019-08-02 | — | — | CN | claimed |
| US-9818690-B2 | Self-aligned interconnection structure and method | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2017-11-14 | — | — | US | claimed |
| US-20170125340-A1 | Self-Aligned Interconnection Structure and Method | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2017-05-04 | — | — | US | claimed |
| US-9627215-B1 | Structure and method for interconnection | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2017-04-18 | — | — | US | claimed |
| US-20170092580-A1 | Structure and Method for Interconnection | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD (TW) | 2017-03-30 | — | — | US | claimed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-12616018-B2 | Graphene barrier layer of interconnect structure | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2026-04-28 | — | — | US | disclosed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | LMITO THERAPEUTICS INC. (KR) | 2026-03-10 | — | — | US | disclosed |
| EP-4146651-B1 | SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS | NINGXIA ACADEMY AGRICULTURE & FORESTRY SCIENCES (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-12410166-B2 | Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2025-09-09 | — | — | US | disclosed |
| US-12378233-B2 | Immunomodulating azalides | ZOETIS SERVICES LLC (US) | 2025-08-05 | — | — | US | disclosed |
| EP-0797576-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-01 | — | — | EP | disclosed |
| EP-0442348-B1 | Imidazole compounds, process for preparation, medicaments based on these compounds and some intermediates | HOECHST AG (DE) | 1996-07-17 | — | — | EP | disclosed |
| WO-1996018628-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5356922-A | Treatment of disturbances in microcirculation | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-18 | — | — | US | disclosed |
| US-5232922-A | Cardiovascular disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-03 | — | — | US | disclosed |
| EP-0442348-A2 | Imidazole compounds, process for preparation, medicaments based on these compounds and some intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-21 | — | — | EP | disclosed |
| US-3941804-A | 1-Heteroarylsulphonyl-2-imino-imidazolidines | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616018-B2 | Graphene barrier layer of interconnect structure | CTCF, EPCAM, ICOSLG | LPO 773/4885MCL1 2467/4885C1S 127/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | LPO 1694/4885MCL1 2937/4885C1S 2918/4885 |
| US-12410166-B2 | Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors | MGAM, MGAM2, ABCC1 | LPO 83/4885MCL1 507/4885C1S 3838/4885 |
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | NQO1, CBR1, NFE2L2 | LPO 584/4885MCL1 921/4885C1S 1327/4885 |
| US-12378233-B2 | Immunomodulating azalides | IL2, MALT1, FCGRT | LPO 2117/4885MCL1 315/4885C1S 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.